These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 32805187)
1. NULP1 Alleviates Cardiac Hypertrophy by Suppressing NFAT3 Transcriptional Activity. Zhang X; Lei F; Wang XM; Deng KQ; Ji YX; Zhang Y; Li H; Zhang XD; Lu Z; Zhang P J Am Heart Assoc; 2020 Aug; 9(16):e016419. PubMed ID: 32805187 [TBL] [Abstract][Full Text] [Related]
2. Opposing roles of FoxP1 and Nfat3 in transcriptional control of cardiomyocyte hypertrophy. Bai S; Kerppola TK Mol Cell Biol; 2011 Jul; 31(14):3068-80. PubMed ID: 21606195 [TBL] [Abstract][Full Text] [Related]
3. Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Liu Q; Chen Y; Auger-Messier M; Molkentin JD Circ Res; 2012 Apr; 110(8):1077-86. PubMed ID: 22403241 [TBL] [Abstract][Full Text] [Related]
4. Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy. Luo Y; Jiang N; May HI; Luo X; Ferdous A; Schiattarella GG; Chen G; Li Q; Li C; Rothermel BA; Jiang D; Lavandero S; Gillette TG; Hill JA Circulation; 2021 Jul; 144(1):34-51. PubMed ID: 33821668 [TBL] [Abstract][Full Text] [Related]
5. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling. Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855 [TBL] [Abstract][Full Text] [Related]
7. Control of Pathological Cardiac Hypertrophy by Transcriptional Corepressor IRF2BP2 (Interferon Regulatory Factor-2 Binding Protein 2). Fang J; Li T; Zhu X; Deng KQ; Ji YX; Fang C; Zhang XJ; Guo JH; Zhang P; Li H; Wei X Hypertension; 2017 Sep; 70(3):515-523. PubMed ID: 28716987 [TBL] [Abstract][Full Text] [Related]
8. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways. Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128 [TBL] [Abstract][Full Text] [Related]
9. Isoproterenol-induced hypertrophy of neonatal cardiac myocytes and H9c2 cell is dependent on TRPC3-regulated Ca Han JW; Kang C; Kim Y; Lee MG; Kim JY Cell Calcium; 2020 Dec; 92():102305. PubMed ID: 33069962 [TBL] [Abstract][Full Text] [Related]
10. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo. Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244 [TBL] [Abstract][Full Text] [Related]
11. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling. Bian ZY; Huang H; Jiang H; Shen DF; Yan L; Zhu LH; Wang L; Cao F; Liu C; Tang QZ; Li H Hypertension; 2010 Feb; 55(2):257-63. PubMed ID: 20026769 [TBL] [Abstract][Full Text] [Related]
12. O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy. Facundo HT; Brainard RE; Watson LJ; Ngoh GA; Hamid T; Prabhu SD; Jones SP Am J Physiol Heart Circ Physiol; 2012 May; 302(10):H2122-30. PubMed ID: 22408028 [TBL] [Abstract][Full Text] [Related]
13. Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A. Maejima Y; Usui S; Zhai P; Takamura M; Kaneko S; Zablocki D; Yokota M; Isobe M; Sadoshima J Circ Heart Fail; 2014 May; 7(3):479-90. PubMed ID: 24526353 [TBL] [Abstract][Full Text] [Related]
14. Targeting Transmembrane BAX Inhibitor Motif Containing 1 Alleviates Pathological Cardiac Hypertrophy. Deng KQ; Zhao GN; Wang Z; Fang J; Jiang Z; Gong J; Yan FJ; Zhu XY; Zhang P; She ZG; Li H Circulation; 2018 Apr; 137(14):1486-1504. PubMed ID: 29229612 [TBL] [Abstract][Full Text] [Related]
15. Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. Ni YG; Berenji K; Wang N; Oh M; Sachan N; Dey A; Cheng J; Lu G; Morris DJ; Castrillon DH; Gerard RD; Rothermel BA; Hill JA Circulation; 2006 Sep; 114(11):1159-68. PubMed ID: 16952979 [TBL] [Abstract][Full Text] [Related]
16. Transcription factor CHF1/Hey2 suppresses cardiac hypertrophy through an inhibitory interaction with GATA4. Xiang F; Sakata Y; Cui L; Youngblood JM; Nakagami H; Liao JK; Liao R; Chin MT Am J Physiol Heart Circ Physiol; 2006 May; 290(5):H1997-2006. PubMed ID: 16603706 [TBL] [Abstract][Full Text] [Related]
17. CHF1/Hey2 promotes physiological hypertrophy in response to pressure overload through selective repression and activation of specific transcriptional pathways. Yu M; Liu Y; Xiang F; Li Y; Cullen D; Liao R; Beyer RP; Bammler TK; Chin MT OMICS; 2009 Dec; 13(6):501-11. PubMed ID: 20001863 [TBL] [Abstract][Full Text] [Related]
18. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis. Mohamed BA; Barakat AZ; Zimmermann WH; Bittner RE; Mühlfeld C; Hünlich M; Engel W; Maier LS; Adham IM J Mol Cell Cardiol; 2012 Oct; 53(4):459-68. PubMed ID: 22884543 [TBL] [Abstract][Full Text] [Related]
19. TAK1 Regulates Myocardial Response to Pathological Stress via NFAT, NFκB, and Bnip3 Pathways. Li L; Chen Y; Li J; Yin H; Guo X; Doan J; Molkentin JD; Liu Q Sci Rep; 2015 Nov; 5():16626. PubMed ID: 26564789 [TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of the chromatin remodeling factor DPF3a induces cardiac hypertrophy through releasing HEY repressors from DNA. Cui H; Schlesinger J; Schoenhals S; Tönjes M; Dunkel I; Meierhofer D; Cano E; Schulz K; Berger MF; Haack T; Abdelilah-Seyfried S; Bulyk ML; Sauer S; Sperling SR Nucleic Acids Res; 2016 Apr; 44(6):2538-53. PubMed ID: 26582913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]